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Background: Pulmonary fibrosis is a debilitating and lethal disease with no effective treatment options.
Understanding the pathological processes at play will direct the application of novel therapeutic avenues. Hypoxia
has been implicated in the pathogenesis of pulmonary fibrosis yet the precise mechanism by which it contributes
to disease progression remains to be fully elucidated. It has been shown that chronic hypoxia can alter DNA
methylation patterns in tumour-derived cell lines. This epigenetic alteration can induce changes in cellular
phenotype with promoter methylation being associated with gene silencing. Of particular relevance to idiopathic
pulmonary fibrosis (IPF) is the observation that Thy-1 promoter methylation is associated with a myofibroblast
phenotype where loss of Thy-1 occurs alongside increased alpha smooth muscle actin (α-SMA) expression. The
initial aim of this study was to determine whether hypoxia regulates DNA methylation in normal human lung
fibroblasts (CCD19Lu). As it has been reported that hypoxia suppresses Thy-1 expression during lung development
we also studied the effect of hypoxia on Thy-1 promoter methylation and gene expression.
Methods: CCD19Lu were grown for up to 8 days in hypoxia and assessed for global changes in DNA methylation
using flow cytometry. Real-time PCR was used to quantify expression of Thy-1, α-SMA, collagen I and III. Genomic
DNA was bisulphite treated and methylation specific PCR (MSPCR) was used to examine the methylation status of
the Thy-1 promoter.
Results: Significant global hypermethylation was detected in hypoxic fibroblasts relative to normoxic controls and
was accompanied by increased expression of myofibroblast markers. Thy-1 mRNA expression was suppressed in
hypoxic cells, which was restored with the demethylating agent 5-aza-20-deoxycytidine. MSPCR revealed that Thy-1
became methylated following fibroblast exposure to 1% O2.
Conclusion: These data suggest that global and gene-specific changes in DNA methylation may play an important
role in fibroblast function in hypoxia.
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Idiopathic pulmonary fibrosis (IPF) is a progressive and
lethal fibrotic lung disease of unknown aetiology that
affects approximately 5 million people worldwide [1].
The disease is associated with progressive scarring of the
lung that subsequently results in loss of lung function.
Incidence of IPF appears to be rising. Recent data from
the UK show a 35% increase in the incidence of IPF in
the primary care setting between 2000 to 2008, with an
overall incidence rate of 7.44 per 100,000 person-years,
and an estimate of over 5,000 new cases diagnosed per
year [2]. There are no effective therapeutic strategies for
the treatment of IPF and patients have a very poor prog-
nosis with a median survival of 2-3 years [3,4]. There
is subsequently a great need for increased comprehen-
sion of disease pathogenesis and the identification of
novel therapeutics.
IPF is characterized by non-resolving injury to the
epithelial cells that line the lung [5]. Alveolar epithelial
cell injury results in the release of cytokines and growth
factors, such as transforming growth factor beta (TGFβ).
Whilst inappropriate epithelial responses may initiate
the injurious process in the lung, it is the activated fibro-
blasts (myofibroblasts) that produce the scar tissue that
ultimately abolishes lung function. As well as the pro-
fibrotic cytokine milieu there is increasing interest in
other local tissue environmental factors that may contrib-
ute to myofibroblast activation. Fibroblast proliferation,
inflammatory cell infiltration and interstitial thickening
potentially combine with alveolar ventilation defects to
increase the consumption and limit the supply of oxy-
gen to the injured lung resulting in local tissue hypoxia.
Pulmonary tissue oxygen levels are hard to quantify but
a role for hypoxia in the progression of pulmonary
fibrosis has been supported by the observation that
there is increased stabilisation of the hypoxia-inducible
transcription factor (HIF-1α) in lung tissue taken from
patients with IPF as well as in mice with bleomycin-
induced pulmonary fibrosis [6]. Whilst a great deal is
known about the role of transcription factors like HIF-1α
in adaptive responses to acute hypoxia, the mechanisms
that regulate transcriptional events in response to chronic
hypoxia are less well understood.
We and others have shown that hypoxia regulates
DNA methylation in cancer-derived cell lines [7-9].
DNA methylation is an epigenetic mechanism whereby a
cytosine residue gains a methyl (CH3) group on the 5
th
carbon of the pyramidine ring to become 5 methylcytosine
(5MeC). This process is catalysed by a group of enzymes
called the DNA methyltransferases (DNMTs). Increased
methylation in regions known as CpG islands of gene pro-
moters is associated with transcriptional repression [10].
Given the importance of DNA methylation in regulating
chromatin condensation and gene expression we proposethat this epigenetic mechanism is crucial for cellular
adaptation to hypoxic conditions. In the case of IPF we
hypothesised that this is important in regulating fibro-
blast phenotype during disease progression.
In support of this hypothesis is an increasing body of
evidence that implicates an altered global DNA methyla-
tion profile in IPF pathogenesis [11,12]. It is of particular
interest that DNA hypermethylation has been associated
with myofibroblast differentiation [13,14]. Recent studies
have demonstrated the contribution of several gene-
specific silencing events mediated by DNA hypermethy-
lation as promoting myofibroblast differentiation as
well as promoting their persistence in fibrotic pulmon-
ary disease [13,15,16]. One such gene is thymocyte dif-
ferentiation antigen-1 (Thy-1). Thy-1 is a membrane
bound glycoprotein. It is an important regulator of cell-
cell and cell-matrix interactions and its expression can
also affect intracellular signalling pathways [17,18]. Thy-1
is expressed on a variety of cell types including thymo-
cytes, T cells and neuronal cells as well as on subsets of
fibroblasts [19]. Thy-1 (-ve) cells are associated with a
myofibroblast phenotype [20-22]. In pulmonary myofibro-
blasts Sanders et al. have demonstrated that Thy-1 loss is
due to epigenetic regulation of the gene [15,23]. Thy-1
was shown to be hypermethylated in fibroblastic foci of
lung tissue taken from patients with IPF, where methyla-
tion of the Thy-1 gene inhibited its expression [15]. Des-
pite the fact that epigenetic regulation of Thy-1 has been
reported as regulating its expression [15,23], there is
currently limited understanding of what environmental
factors govern the availability of Thy-1 (+ve) and Thy-1
(-ve) cells. Interestingly it has been demonstrated that
Thy-1 expression is suppressed in lungs of hypoxic
mice and this is associated with increased TGFβ1 acti-
vation [24]. Whether this suppression was due to in-
creased DNA methylation in the Thy-1 promoter was
not reported.
Given the results from these studies investigating Thy-1
expression and regulation, along with our previous find-
ings that hypoxia can impact a cells DNA methylation
profile, the aim of this study was to investigate hypoxic
regulation of DNA methylation in commercially available
normal human pulmonary fibroblasts. We hypothesised
that hypoxic regulation of DNA methylation promotes
myofibroblast differentiation and that hypoxia induced




Commercially available normal human pulmonary fibro-
blasts (CCD19Lu) were acquired from American Type
Culture Collection. Cells were cultured in minimum es-
sential medium (MEM; Sigma) supplemented with 10%
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and penicillin/streptomycin (Gibco) in a 5% CO2 humidi-
fied incubator kept at 37°C. When a chronic hypoxia
environment was required, a 1% oxygen (O2) atmosphere
was created using a hypoxic chamber (Coy Laboratories).
Cells were grown for up to 8 days in 1% oxygen (5% CO2).
Treatments
For demethylation analysis, cells were treated with 1 μM
5-aza-20-deoxycytidine (5-aza2dC; Sigma) and reple-
nished every second day for 8 days.
Flow cytometry
Cells were harvested by trypsinization and fixed in Carnoy’s
Solution (3:1 methanol/acetic acid). Immuno-staining
was then conducted using a monoclonal anti-5MeC
(Eurogentec) antibody. Prior to staining with anti-
5MeC cells were pre-incubated with 1 M HCl at 37°C
for 1 h. IgG1 negative controls were used at equivalent
concentrations as the primary antibody. Antibody binding
was visualised using fluorescein isothiocyanate isomer 1
(FITC) conjugated rabbit anti-mouse secondary anti-
body (Dako) and analysed using a CYAN flow cytometer.
Results were assessed using SUMMIT software (Dako).
Quantitative real-time PCR (QPCR)
RNA was isolated from cells with NucleoSpin RNA II
Kit (Macherey-Nagel) prior to first strand cDNA synthe-
sis using SuperScript II RT (Invitrogen). QPCR primers
were designed so that one of each primer pair was exon/
exon boundary spanning to ensure only mature mRNA
was amplified. The sequences of the gene-specific primers
used are as follows;
α-SMA; 50-CGTTACTACTGCTGAGCGTGA-30
(forward), 50-AACGTTCATTTCCGATGGTG
3'(reverse) collagen type I (α1);
50- GAACGCGTGTCATCCCTTGT-30(forward),
50 -GAACGAGGTAGTCTTTCAGCAACA -30(reverse)
collagen type III (α1); 50-
AACACGCAAGGCTGTGAGACT -30(forward),
50- GCCAACGTCCACACCAAATT -30(reverse) Thy-1;
50- ATGAACCTGGCCATCAGTCT-30 (forward),
50-CACGTGCTTCTTTGTCTCA-30 (reverse).
Following extensive quantification of various potential
housekeeping genes in normoxia and hypoxia, the ex-
pression of beta-2-microglobulin (B2M) was found to be
unaffected by experimental conditions (data not shown)
and was therefore deemed an appropriate housekeeper.
The sequences for B2M were as follows: 50- AGGCTAT
CCAGCGTACTCCA-30 (forward), 50-CCAGTCCTTGC
TGAAAGACA-30 (reverse).QPCR was performed using Platinum SYBR Green
QPCR SuperMix-UDG (Invitrogen). Amplification and
detection were carried out using Mx3000P System (Stra-
tagene). The PCR cycling program consisted of 40 three-
step cycles of 15 s/95°C, 30 s/TA and 30 s/72°C. Each
sample was amplified in duplicate. In order to confirm
signal specificity, a melting program was carried out
after the PCR cycles were completed. The samples were
quantified using the delta delta CT method.
Methylation specific PCR
The methylation status of Thy-1 was investigated using
Methylation Specific PCR (MSPCR). Total genomic DNA
was isolated from normoxic and hypoxic CCD19Lu cells
using DNeasy DNA extraction kit (Qiagen), according to
manufacturer's instructions. Prior to MSPCR, 1 μg of
DNA was bisulfite-treated using the EZ DNA Methylation
kit (Zymo Research) according to manufacturer's instruc-
tions. Previously published Thy-1 MSPCR primers were
used to discriminate between methylated and unmethy-
lated DNA [15]; methylated forward, 50-TATTTTTATAT
TAATGCGGGATCGT-30, methylated reverse, 50-CGAT
TACTACACCCAACTCGAA-30, unmethylated forward,
50-TTATTTTTATATTAATGTGGGATTGT-30, unmethy-
lated reverse 50-TCCAATTACTACACCCAACTCAAA -30.
MSPCR products were visualised by electrophoresis on
2% SYBRsafe stained agarose gels.
Western blot
α-SMA expression was measured in normoxic and hypoxic
CCD19Lu. Whole cell protein extractions were performed
using radioimmuoprecipitation buffer (RIPA buffer, Milli-
pore) with a 1 × protease inhibitor cocktail (Complete
Mini, Roche). All proteins were quantified and subse-
quently normalised using a BCA kit (Pierce). Polyacryl-
amide gels were used to separate proteins by size and
they were then transferred onto a polyvinylidene fluoride
(PVDF) membrane (Immobilion-P transfer membrane,
Millipore). Following a blocking step in 5% milk, the
membranes were incubated overnight at 4°C in primary
antibody directed towards α-SMA (mouse anti αSMA;
Sigma). After washing, the membranes were then incu-
bated in a HRP conjugated goat anti mouse secondary
antibody (Santa Cruz). They were then washed and devel-
oped. α-tubulin (mouse anti α tubulin; Cedarlane) was
used as a loading control.
Immunocytochemistry
CCD19Lu were seeded onto wells of coverslides. Follow-
ing appropriate treatments, the cells were washed in
PBS and then fixed and permeabilised using 70% metha-
nol. After blocking, the slides were incubated in primary
antibody (mouse anti α-SMA; Sigma) for 1 h at room
temperature. They were then washed and incubated for
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gated secondary antibody (goat anti mouse Invitrogen).
The cells were counterstained with DAPI (Sigma) and
kept in the dark until images were taken using a micro-
scope capable of detecting florescent images (Carl Zeiss
Axio Imager I).
Statistical analysis
All statistical analyses were performed using Graph Pad
Prism software (Version 4, San Diego, CA). Comparisons
between groups were made using independent t-test or
analysis of variance (ANOVA), where appropriate. All data
are presented as mean ± standard deviation of the mean
(SD). Results were deemed significant when p < 0.05 (*),
p < 0.01 (**) or p < 0.001(***).
Results
Hypoxia causes global DNA hypermethylation in human
pulmonary fibroblasts
We and others have previously reported that hypoxia
can alter the DNA methylation profile of tumour derived
epithelial cells [7-9]. The impact of chronic hypoxia on
global DNA methylation levels in normal human pul-
monary fibroblasts was investigated using quantitative
flow cytometry. Growing CCD19Lu in 1% O2 for 4 and
8 days significantly increased levels of 5MeC in these
cells (Figure 1), a result that is in support of a role for
hypoxia in modifying a cell’s epigenetic profile.
DNA methylation is involved in regulating gene ex-
pression, where an increased level of methylated cyto-
sines in a gene promoter is associated with silencing ofFigure 1 Hypoxia causes global hypermethylation in human
pulmonary fibroblasts. CCD19Lu were grown for 4 and 8 days in
1% O2 and levels of DNA methylation were measured using an
antibody directed towards 5 methylcytosine (5MeC) and quantitative
flow cytometry. Hypoxic cells had significantly increased levels of
5MeC, measured as mean channel fluorescence (MCF), compared to
levels in normoxic cells. Results are mean +/- SD for n = 3
experiments and statistical analysis was performed using one way
anova where p < 0.05 (*) and p < 0.01 (**).that gene. While a role for hypoxia in promoting myofi-
broblast differentiation has been acknowledged [25-28],
more recently a role for DNA methylation in myofibro-
blast differentiation has also been proposed [13,14]. We
therefore wished to investigate if the global hypermethy-
lation in hypoxic pulmonary fibroblasts is associated
with profibrotic phenotypic changes in the fibroblasts at
similar hypoxic time points.Hypoxia increases α-SMA, collagen I and III in CCD19Lu
Hypoxia promotes myofibroblast differentiation. Pulmonary
fibroblasts grown for 8 days in hypoxia expressed
increased mRNA levels of α-SMA, collagen I and collagen
III (Figure 2A). In addition α-SMA was increased at pro-
tein level (Figure 2B). Immunocytochemistry demon-
strated that the increased α-SMA formed stress fibres
consistent with myofibroblast morphology (Figure 2C).
Given that increased DNA methylation causes gene
silencing, the increased expression of α-SMA, collagen
I and III observed in hypoxic cells was not due to direct
methylation of their promoters. Thus we investigated the
expression of Thy-1, a gene whose expression is known
to be regulated by DNA methylation [15]. Additionally
Thy-1 (-ve) pulmonary fibroblasts are associated with a
more differentiated myofibroblast phenotype [20-22].
Thus we hypothesised that Thy-1 expression may be
regulated by DNA methylation in hypoxic CCD19Lu and
this regulation contributed to a more fully differentiated
myofibroblast like phenotype evident in the hypoxic cells.Hypoxia decreased expression of Thy-1
QPCR for Thy-1 revealed that hypoxia significantly
reduced expression of the gene in fibroblasts after 4 and
8 days exposure to a 1% oxygen environment (Figure 3).
In order to investigate if this reduction in gene expression
was due to DNA hypermethylation in hypoxic CCD19Lu,
two avenues of investigation were used to quantify Thy-1
promoter methylation. MSPCR revealed that the Thy-1
promoter became hemimethylated in 8 day hypoxic cell
samples (Figure 4) suggesting that DNA methylation may
be involved in reducing Thy-1 expression.The demethylating agent 5-aza2dC reversed hypoxic
suppression of Thy-1 mRNA
Treating hypoxic fibroblasts with the DNMT inhibitor
5-aza2dC reversed hypoxic suppression of Thy-1 (Figure 5A)
which provides further evidence that this gene is suppressed
in hypoxia due to increased DNA methylation of its
promoter. In addition, expression of Thy-1 in hypoxic
5-aza2dC treated samples was accompanied by reduced
expression of mRNA α-SMA (Figure 5B) as well as reduced
α-SMA protein expression (Figure 5C).
Figure 2 Expression of myofibroblast markers are increased in hypoxic pulmonary fibroblasts. A. Normoxic or hypoxic (1% oxygen,
8 days) pulmonary fibroblasts were analysed for mRNA expression of alpha smooth muscle actin (α-SMA), collagen I and collagen III using
quantitative real-time PCR. Hypoxic cells expressed increased levels of α-SMA (p < 0.05), colIagen I (p < 0.001) and collagen III (p < 0.05) compared
to normoxic controls. B. α-SMA protein expression was increased in hypoxic cells. This is a sample blot from n = 3 experiments. The increase in
α-SMA was statistically significant when densitometry was performed. Results are mean +/- SD for n = 3 experiments. Students t test was used for
statistical analysis. C. Immunocytochemistry for α-SMA (red) demonstrated that increased levels of the protein was present in hypoxic cells where
it formed microfilaments. Cells were counterstained with nuclear specific DAPI (blue).
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In support of other published research [7-9,29], the
results presented here highlight hypoxia as an important
regulator of a cell’s epigenetic profile. We show that
chronic hypoxia induces a significant increase in global
DNA methylation in human pulmonary fibroblasts that
is associated with Thy-1 promoter methylation and the
activation of a myofibroblast phenotype. These results
are consistent with recent evidence of hypermethylation
in tumour derived prostate epithelial cells exposed to
chronic (>30 days) hypoxia [9]. In our study hypoxic
human pulmonary fibroblasts had increased levels of
5MeC compared to normoxic controls although this
change occurred at earlier hypoxic time points as thefibroblasts displayed a detectable increase in 5MeC as
early as 4 days. Because hypermethylation was more pro-
nounced at 8 days hypoxia we chose to conduct all fur-
ther experiments at this time point. Given that at 4 days
there were changes in global DNA methylation, it is
likely that methylation events participate in myofibro-
blast differentiation at earlier hypoxic time points also,
although this was not investigated further as part of
this study.
Given the presence of tissue hypoxia in numerous
disease processes, its modulation of epigenetic processes
is an important observation. Global hypermethylation in
hypoxic pulmonary fibroblasts is particularly significant
given the fact that increased levels of global DNA
Figure 3 Hypoxic human pulmonary fibroblasts express
decreased levels of Thy-1 mRNA. CCD19Lu were grown for 4 and
8 days in 1% oxygen and expression of Thy-1 was quantified using
quantitative real time PCR. There was a significant reduction in Thy-1
expression in hypoxic cells after 4 and 8 days, p < 0.05 (*) and
p < 0.01 (**), respectively, compared to normoxic control expression.
Results are mean +/- SD for n = 4 experiments and students t test
was used for statistical analysis.
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as well as in bleomycin treated mouse lung fibroblasts
when their methylation status is compared to healthy con-
trol cells [13]. Indeed there is a growing body of evidence
for a role for global epigenetic modifications in controlling
the progression of myofibroblast differentiation [14]. In
a folic acid-induced kidney fibrosis model, the DNMT
inhibitor 5 azacytidine attenuated the disease [30], a
further indication of the involvement of DNA methyla-
tion in fibrotic scar formation.
Gene silencing due to DNA methylation is thought to
occur in one of two ways. Methylated DNA can directly
impede transcription factor binding or alternatively
methylated DNA attracts methyl binding domain (MBD)
containing proteins, such as MeCP2 [31], which help
promote a repressive chromatin environment by subse-
quent interaction between histone modifiers. This hasFigure 4 The Thy-1 promoter becomes hemimethylated in
hypoxic pulmonary fibroblasts. Human pulmonary fibroblasts
were grown in hypoxia for 4 and 8 days. Genomic DNA was bisulfite
treated and methylation specific PCR (MSPCR) using unmethylated
(U) and methylated (M) specific primers were used to investigate the
methylation status of the Thy-1 promoter. MSPCR revealed Thy-1
promoter hemimethylation in hypoxic cells (n = 3) that was not
present in normoxic controls (n = 3).been implicated in both pulmonary and liver fibrosis
[32-34] and has been supported by MeCP2 knockout
mice which display decreased levels of fibrosis compared
to wild type models of both diseases [33,35]. Whilst indir-
ect, the correlations between increased MeCP2 expression
and worsening fibrosis also support a role for DNA hyper-
methylation in fibrotic disease pathogenesis.
Increased DNA methylation has the potential to induce
phenotypic changes in a cell. Distinguishing them from
fibroblasts, myofibroblasts express increased levels of
mesenchymal markers such as α-SMA as well as synthe-
sise significantly more extracellular matrix components
like collagen I and III. Here we have demonstrated an
association between DNA hypermethylation and an
exaggerated myofibroblast phenotype in hypoxia. Previous
groups have reported gene specific methylation events as
contributing to such changes in pulmonary fibroblast
phenotype. Huang et al. reported that the global hyper-
methylation in IPF patient myofibroblasts caused silencing
of the prostaglandin receptor E2 (PTGER2) gene and pro-
posed that methylation of this gene contributed to the
myofibroblast phenotype [13] while Hagood et al. have
provided evidence of Thy-1 methylation contributing to
such differentiation [15]. In Thy-1 (-ve) rat lung fibro-
blasts treatment with a histone deacetylase inhibitor
(HDACi) reactivated Thy-1 expression [23]. Interest-
ingly other groups have also reported anti-fibrotic
effects of HDACi on IPF fibroblasts [36]. Reports such
as these suggest that histone modifications combined
with alterations in DNA methylation participate to pro-
mote myofibroblast differentiation. It is therefore un-
likely that methylation of one single gene results in a
complete differentiation in cell phenotype, although it
is plausible that silencing of one gene contributes to
the progression of myofibroblast development.
Thus in globally hypermethylated hypoxic cells we
chose to investigate the methylation status of Thy-1.
The Thy-1 promoter contains a high frequency of CpG
dinucleotides. Methylation of this region has previously
been shown to control gene expression and Thy-1 has
been reported as methylated in fibroblasts in fibrotic foci
in IPF patient tissue [15]. Although in vivo hypoxia can
reduce Thy-1 expression in mouse lung fibroblasts [24],
methylation of the Thy-1 promoter has not been asso-
ciated with hypoxia-induced suppression. Here we have
demonstrated that methylation of Thy-1 occurs in hyp-
oxic human fibroblasts and significantly reduces Thy-1
transcription which can be restored by treatment with
the demethylating agent 5-aza2dC. Interestingly, 5-aza2dC
had no effect on Thy-1 expression in normoxia while in
hypoxic cells 5-aza2dC treatment resulted in a 2-fold
increase in expression. Given that hypoxia can regulate
chromatin remodelling [37], the addition of 5-aza2dC
in this environment may further enhance transcription
Figure 5 The DNA hypomethylating agent 5-aza-20-deoxycytidine restores mRNA expression of Thy-1 that is accompanied by a
decrease in α-SMA expression. Normoxic and hypoxic fibroblasts were treated with 1 μM 5-aza-20-deoxycytidine (5-aza2dC) and quantitative
real-time PCR was used to measure Thy-1 mRNA expression. A. 5-aza2dC inhibited hypoxia induced suppression of Thy-1 whereas in normoxia
Thy-1 expression remained unchanged with 5-aza2dC treatment. B. Restoration of Thy-1 in 5-aza2dC treated hypoxic cells was accompanied by a
reduction in α-SMA mRNA. C. Immunocytochemistry for α-SMA (red) demonstrated that restoration of Thy-1 using 5-aza2dC treatment decreased
expression of α-SMA in hypoxic cells. Cells were counterstained with nuclear specific DAPI (blue). Results are mean +/- SD for n = 3 experiments
and students t test was used for statistical analysis.
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in normoxia.
In this study we demonstrate that Thy-1 methylation is
associated with differentiation towards a myofibroblast
phenotype which is in accordance with previous evidence
which has shown that there is a strong correlation be-
tween Thy-1 loss and increased expression of mesenchy-
mal markers. Thy-1 (-ve) rat fibroblasts as well as Thy-1-/-
mice express increased mesenchymal markers like α-SMA
even at basal levels when compared to expression in posi-
tive controls [22,24]. Thy-1-/- mouse lungs also express
increased basal levels of total collagen compared to wild
type controls [24]. These observations are directly com-
parable to hypoxic fibroblast data shown here. Thy-1
suppression is accompanied by increased expression of
α-SMA, collagen I and III. Loss of Thy-1 surface pro-
tein has previously been shown to increase activation of
latent TGFβ1 [17,38] and this could be a mechanism
involving Thy-1 by which hypoxia promotes myofibro-
blast differentiation.
The increase in mesenchymal markers in hypoxia sug-
gests that the promoter regions of these genes do not
become directly hypermethylated. It is therefore likely
that hypermethylation of other genes contributes to the
change in phenotype. The phenotype seen in hypoxia isindicative of a Thy-1(-ve) fibroblast and DNA methyla-
tion alterations, be it via regulation of Thy-1 or other-
wise, are implicated in playing an important role in this
change. In support of this, Thy-1 re-expression in hyp-
oxic cells treated with 5-aza2dC exhibited a significant
suppression of α-SMA gene and protein expression. Al-
though we have not investigated any other gene specific
methylation events it is likely there are other ‘anti-
fibrotic’ genes that may be silenced by a similar mechan-
ism. For example PGER2 and RASAL display anti-fibrotic
effects and have previously been reported as methylated in
myofibroblasts [13,30].
CCD19Lu are a commercially available human fibro-
blast cell line. These cells are not transformed and do
senesce so should act as a normal pulmonary interstitial
fibroblast. However, growing these cells on polystyrene
plates has the potential to alter the cells phenotype. This
is a limitation of this study and the use of primary human
fibroblasts could reflect the cell type more accurately.
Conclusion
These results implicate hypoxia as an important regulator
of fibroblast phenotype by causing DNA hypermethylation
in these cells. Hypoxic exposure was associated with the
development of a myofibroblast. Additionally, we have
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moter becomes methylated in hypoxic fibroblasts resulting
in reduced gene expression. We propose that this methy-
lation event is likely to contribute to the observed change
in phenotype. DNA methylation changes are likely im-
portant events in the pathogenesis of pulmonary fibrosis
and understanding the mechanisms and effected genes
in this process may in the future provide new thera-
peutic targets.
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